Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Cisplatin and Gemcitabine in Advanced Head and Neck Cancer
NCT00003264Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 1997
- Primary completion
- Feb 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by Fox Chase Cancer Center. Primary endpoint: Objective Response Rate at 28 days. Started Oct 1997; status: completed.
02
Drugs
gemcitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00003264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003264.